In addition, Osawa et al. described that combining PRI-724 with anti-PD-L1 treatment resulted in regression of tumor growth in a mouse model of colon cancer and provoked more profound antitumor CD8+ T cell response compared with each monotherapy 146. The gene discussed is CD8A; the disease is neoplasm.